Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposomes + Platinum for GEP-NEC
NCT06485739Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2024
- Primary completion
- Jul 2028
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Intracranial Objective response rate at 1 year. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on NCT06485739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485739.